Publications

2018

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018 Nov 1;175(4):998-1013.

Kasumova GG, Shi A, Cintolo-Gonzalez JA, Chein I, Frederick DT, Alpatov R, Michaud WA, Plana D, Panka DJ, Corcoran RB, Flaherty KT. Abstract A35: BRAF inhibition increases exosomal PD-L1 protein expression in melanoma.

Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell. 2018 Nov 1;175(4):984-97.

Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nature medicine. 2018 Oct;24(10):1545.

Zhang G, Wu LW, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Randell S, Sadek N, Beroard A, Xiao M, Tian T. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research. 2018 Jan 1:clincanres-2773.

2017

Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, Liberti MV, Magpusao AN, Stein EM, Tingley JP, Frederick DT. Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence. Cell reports. 2017 Dec 5;21(10):2796-812.

Kasumova GG, Haynes AB, Boland GM. Lymphatic versus Hematogenous Melanoma Metastases: Support for Biological Heterogeneity without Clear Clinical Application. Journal of Investigative Dermatology. 2017 Dec 1;137(12):2466-8.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer discovery. 2018 Feb 1;8(2):216-33.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discovery. 2018 Feb 1;8(2):196-215.

Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, Frederick DT. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nature Communications. 2017 Oct 26;8(1):1136.

Rand AJ, Flejter WL, Dowling CA, Brooke LM, Boland GM, Kroshinsky D, Rosenblum IR, Hernandez‐Perez M, Reimann JD. Atypical ALK‐positive Spitz tumors with 9p21 homozygous deletion: Report of two cases and review of the literature. Journal of cutaneous pathology. 2018 Feb;45(2):136-40.

Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017 Oct;550(7674):133.

Vitiello M, Tuccoli A, D’Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget. 2017 Apr 11;8(15):25395.

Raigani S, Cohen S, Boland GM. The role of surgery for melanoma in an era of effective systemic therapy. Current oncology reports. 2017 Mar 1;19(3):17.